Moderna (MRNA) Change in Account Payables (2018 - 2026)

Moderna (MRNA) has 9 years of Change in Account Payables data on file, last reported at -$120.0 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 23.08% year-over-year to -$120.0 million in Q1 2026; TTM through Mar 2026 was -$56.0 million, a 171.79% decrease from a year earlier, with the FY2025 full-year figure at -$92.0 million, down 33.33% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$120.0 million, down from $22.0 million in the prior quarter.
• Over the last five years, Change in Account Payables for MRNA reached as high as $179.0 million in Q3 2023 and fell as low as -$303.0 million in Q1 2024.
• Historically, Change in Account Payables has averaged -$1.6 million across 5 years, with a median of $21.0 million in 2023.
• Across the five-year window, Change in Account Payables jumped 905.56% in 2022 and sank 234.29% in 2023, its largest moves.
• Year by year, Change in Account Payables stood at $151.0 million in 2022, then tumbled by 86.09% to $21.0 million in 2023, then soared by 61.9% to $34.0 million in 2024, then tumbled by 35.29% to $22.0 million in 2025, then plunged by 645.45% to -$120.0 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$120.0 million in Q1 2026, $22.0 million in Q4 2025, and $89.0 million in Q3 2025.